论文部分内容阅读
目的:观察刺五加脑灵液联合舍曲林治疗肠易激综合征的临床疗效。方法:选取2008年6月~2012年6月间在本院治疗的89例肠易激综合征患者,随机分为对照组43例和观察组46例,对照组给予口服舍曲林,观察组给予舍曲林和刺五加脑灵液,疗程3月。于治疗前后使用汉密尔顿抑郁量表(HAMD)和焦虑量表(HAMA)进行神经心理学评分,并观察2组患者不良反应情况,疗程结束后统计疗效和单项症状(腹痛、腹泻、黏液便)有效率。结果:治疗前2组患者HAMD、HAMA评分比较,差异无显著性意义(P>0.05);治疗后2组HAMD、HAMA评分均有下降,观察组HAMD评分与治疗前比较,差异有显著性意义(P<0.05);2组HAMA评分与治疗前比较,差异有显著性意义(P<0.05),且观察组HAMA评分明显低于对照组,差异有显著性意义(P<0.05),表明观察组患者焦虑和抑郁情绪改善更佳。治疗后2组腹痛改善有效率分别为93.5%和72.1%,差异有显著性意义(P<0.05);观察组腹泻改善有效率为80.4%,对照组为58.1%,观察组明显好于对照组,差异有显著性意义(P<0.05);观察组黏液便改善率67.4%好于对照组51.2%,但差异无显著性意义(P>0.05)。服药后2组均未出现严重不良反应。结论:刺五加脑灵液联合舍曲林治疗肠易激综合征患者疗效显著,对患者的焦虑和抑郁情绪有明显改善,不良反应较轻,值得临床推广使用。
Objective: To observe the clinical effects of acanthopanax senticosus combined sertraline on irritable bowel syndrome. Methods: A total of 89 patients with IBS treated in our hospital from June 2008 to June 2012 were randomly divided into control group (n = 43) and observation group (n = 46). The control group was given oral sertraline and the observation group Give sertraline and Acanthopanax brain fluid, treatment in March. Before and after treatment, the Hamilton Depression Inventory (HAMD) and Anxiety Scale (HAMA) were used to evaluate the neuropsychological scores. Adverse reactions were observed in two groups. After the treatment, the statistical effects and individual symptoms (abdominal pain, diarrhea, mucus) effectiveness. Results: There was no significant difference in HAMD and HAMA score between the two groups before treatment (P> 0.05). HAMD and HAMA scores decreased in both groups after treatment, and there was significant difference between the two groups (P <0.05). The HAMA score of the two groups was significantly different from that before treatment (P <0.05), and the HAMA score of the observation group was significantly lower than that of the control group (P <0.05) Patients with anxiety and depression improved better. After treatment, the effective rates of two groups of abdominal pain were 93.5% and 72.1% respectively, the difference was significant (P <0.05); the effective rate of diarrhea in observation group was 80.4% and that of control group was 58.1%, the observation group was significantly better than the control group (P <0.05). The improvement rate of mucus in the observation group was 67.4% better than that in the control group (51.2%), but the difference was not significant (P> 0.05). Serious adverse reactions were not observed in the two groups after taking the medicine. Conclusion: Acanthopanax senticosa combined sertraline treatment of patients with irritable bowel syndrome significant effect on patients with anxiety and depression have significantly improved, mild adverse reactions, it is worth promoting the use of the clinic.